**SALES WORLDWIDE**

$8.9B in sales

+10.6% on organic basis

**SALES PERFORMANCE ACROSS ABBOTT**

$3.2B MEDICAL DEVICES

$2.6B DIABETES

$1.1B FORMULA & PHARMACEUTICALS

$1.9B NUTRITION

**RAISED FULL-YEAR 2020 EPS GUIDANCE**

at least $3.55 Adjusted diluted earnings per share

**TAKING COVID-19 TESTING TO A NEW LEVEL**

>100MM Tests completed on AbbVie’s platform in 2020

$881MM COVID-19 and flu test volume

**LEADERSHIP ACROSS OUR STRONG PRODUCT PORTFOLIO**

**Diagnostics**

SALES UP 39% on an organic basis

- Growth in key business segments driven by TIVDIA and Rapid Diagnostic COVID-19
- Further expansion of our COVID-19 testing technology platform

**FreeStyle Libre**

SALES UP 36% in the wearable market

- Amended EU MDR for FreeStyle Libre 14+
- EU approval for FreeStyle Libre 4K in the United States
- EU approval for the FreeStyle Libre 14+ glucose management system in Germany

**Advances in Heart Devices**

- Amended CE mark for next generation MitraClip heart device
- EU CE mark for next generation MitraClip heart device
- Amended CE mark for next generation MitraClip heart device

Abbott Laboratories encourages the use of scientifically recognized clinical guideline and best practice resources for the diagnosis and treatment of patients. For detailed information, please consult the appropriate resources and packages.